Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
(Thomson Reuters ONE) -
Novartis International AG /
Novartis announces ground-breaking collaboration with IBM Watson Health on
outcomes-based care in advanced breast cancer
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Collaboration will use real-world patient data and cognitive computing with
aim of improving outcomes in advanced breast cancer
* Brings Novartis innovation and breast cancer expertise together with IBM
Watson Health proficiency in data analytics and machine learning
* Collaboration initiating in breast cancer given Novartis heritage and
expertise; opportunity to expand to enhance outcomes for patients with other
cancers
Basel, June 5, 2017 - Novartis today announced a first-of-its-kind collaboration
with IBM Watson Health on an initiative to optimize cancer care and improve
patient outcomes. The two companies will collaborate to explore development of a
cognitive solution that uses real-world data and advanced analytical
techniques with the aim to provide better insights on the expected outcomes of
breast cancer treatment options.
With one of the broadest portfolios and largest number of advanced breast cancer
compounds in development, breast cancer is a priority oncology focus area for
Novartis. Scientific understanding of advanced breast cancer is improving and
the treatment landscape is expanding, but new therapies and real-world evidence
can raise more questions around the optimal treatment plan for individual
patients.
This collaboration will join Novartis expertise in breast cancer with IBM Watson
Health skill in data analytics and machine learning to determine which
combinations and sequences may lead to the best patient outcomes. The initiative
primarily will use real-world patient data.
"Through this collaboration with IBM Watson Health, we will use real-world
breast cancer data and cognitive computing to identify solutions that may help
physicians better understand which therapy may be best for which patients or
advise clinical practice guidelines, with the goal of improving patient outcomes
and experiences," said Bruno Strigini, CEO, Novartis Oncology. "We hope this
collaboration also uncovers care efficiencies that can be applied beyond breast
cancer."
"At Watson Health, we are tackling some of the world's greatest challenges at
the nexus of science and data, and we are proud to work with Novartis to better
individualize advanced breast cancer treatment approaches in an effort to
enhance patient care," said Anil Jain, MD, chief medical informatics officer,
IBM Watson Health. "As the industry shifts toward value-based care, it's
critical for clinicians to understand the real-world outcomes of therapeutics on
subsets of their patients, and our goal ultimately is to put those insights into
oncologists' hands. With the deep expertise of Novartis in breast cancer, we are
confident that this collaboration may provide transformative tools for
clinicians and patients to make more informed treatment decisions."
Watson is the first commercially available cognitive computing capability
representing a new era in computing. The system, delivered through the cloud,
analyzes high volumes of data, understands complex questions posed in natural
language and proposes evidence-based answers. Watson continuously learns,
gaining in value and knowledge over time, from previous interactions.
For more than 25 years, Novartis has been at the forefront of driving scientific
advancements for breast cancer patients. Novartis has four marketed products in
breast cancer: Kisqali(®*) (ribociclib), Afinitor(®) (everolimus),
Tykerb(®)/Tyverb(®) (lapatinib) and Femara(®) (letrozole). Novartis also has the
largest number of breast cancer compounds in development, including BYL719
(alpelisib), an alpha-specific PI3K inhibitor; LSZ102, an oral SERD; LJM716, a
fully human, anti-HER3 IgG1 antibody; and MCS110, a colony-stimulating factor 1
(CSF1) inhibitor.
*Kisqali(®) is only commercially available in the United States.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "will," "aim," "initiating," "opportunity," "initiative," "to
explore," "expected," "in development," "priority," "focus area," "improving,"
"expanding," "can," "may," "goal," "hope," "in an effort to," "confident," or
similar terms, or by express or implied discussions regarding potential
marketing approvals for BYL719, LSZ102, LJM716, MCS110, and the other compounds
in development by Novartis for breast cancer, potential new indications,
labeling or marketing approvals for Kisqali, Afinitor, Tykerb/Tyverb or Femara,
or regarding potential future revenues from such compounds in development and
marketed products, and potential future revenues from the collaboration with IBM
Watson Health. You should not place undue reliance on these statements. Such
forward-looking statements are based on the current beliefs and expectations of
management regarding future events, and are subject to significant known and
unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the forward-looking
statements. There can be no guarantee that BYL719, LSZ102, LJM716, MCS110, or
any of the other compounds in development by Novartis for breast cancer will be
submitted or approved for sale in any market, or at any particular time. Neither
can there be any guarantee that the collaboration with IBM Watson Health will
achieve any or all of its intended goals and objectives, or be commercially
successful. Nor can there be any guarantee that Kisqali, Afinitor, Tykerb/Tyverb
or Femara will be submitted or approved for sale, or for any additional
indications or labeling, in any market, or at any particular time. Neither can
there be any guarantee that any of BYL719, LSZ102, LJM716, MCS110, the other
compounds in development by Novartis for breast cancer, Kisqali, Afinitor,
Tykerb/Tyverb or Femara will be commercially successful in the future. In
particular, management's expectations regarding such compounds in development
and marketed products, and the collaboration with IBM Watson Health, could be
affected by, among other things, the uncertainties inherent in research and
development, including clinical trial results and additional analysis of
existing clinical data; regulatory actions or delays or government regulation
generally; the company's ability to obtain or maintain proprietary intellectual
property protection; general economic and industry conditions; global trends
toward health care cost containment, including ongoing pricing and reimbursement
pressures; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
118,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis and (at)NovartisCancer at
http://twitter.com/novartis and http://twitter.com/novartiscancer
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Julie Masow
Novartis Global Media Relations Novartis Oncology Media Relations
+41 61 324 7999 (direct) +1 862 778 7220 (direct)
+41 79 593 4202 (mobile) +1 862 579 8456 (mobile)
eric.althoff(at)novartis.com julie.masow(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2110340/802057.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.06.2017 - 13:15 Uhr
Sprache: Deutsch
News-ID 546285
Anzahl Zeichen: 10688
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
